Clinical Trials Logo

Central Nervous System Tumors clinical trials

View clinical trials related to Central Nervous System Tumors.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05235074 Recruiting - Clinical trials for Central Nervous System Tumors

OH2 Oncolytic Viral Therapy in Central Nervous System Tumors

Start date: November 16, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

In the first phase, it mainly explores the safety, tolerability and preliminary effectiveness of two doses of OH2 injection in the treatment of patients with recurrent central nervous system tumors; to evaluate the biodistribution and virus shedding of OH2 injection administered in the tumor cavity; to evaluate the level of anti-HSV2 antibody in patients when OH2 injection is administered intracavitary to tumor; to determine the phase II recommended dose (RP2D) of OH2 injection in the treatment of recurrent glioblastoma. Phase IIa, to evaluate the preliminary efficacy of OH2 injection in the treatment of patients with recurrent glioblastoma after surgery, and to further evaluate the safety of OH2 in the treatment of relapsed glioblastoma.

NCT ID: NCT05081180 Recruiting - Clinical trials for Central Nervous System Tumors

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

Start date: December 3, 2021
Phase: Phase 1
Study type: Interventional

This study consists of 2 parts: Dose Escalation Part 1 and Dose Expansion Part 2. The Dose Escalation Part 1 will evaluate the safety and tolerability of Avelumab in combination with Lenvatinib and determine the recommended Avelumab and Lenvatinib dose for expansion. Dose Expansion Part 2 will assess the efficacy of Avelumab in combination with Lenvatinib by Progression-free Survival in participants with pre-defined primary central nervous system (CNS) tumors.

NCT ID: NCT00607984 Recruiting - Tumors Clinical Trials

Administration of High Dose Thiotepa and Melphalan With Autologous Hematopoietic Stem Cell Transplant in Children and Adolescents With Solid Tumors

Start date: June 2006
Phase: N/A
Study type: Interventional

The prognosis of children and adolescents with high risk tumors of the central nervous system and other miscellaneous solid tumors is poor despite modern treatment protocols. Frequently, physicians suggest additional therapy with high dose chemotherapy after a good initial response to standard doses of treatment has been obtained, so as to reduce the chance that the tumor will recur. We propose a regimen of high dose thiotepa and melphalan followed by rescue of the patient's previously stored hematopoietic (blood manufacturing) system with blood stem cells. The aim of this study is to prove that this therapy is tolerable in children and adolescents, that it results in tolerable levels of toxicity, and that it improves the survival of this group of children as compared to standard therapy given in the past